MedPacto Submits Phase 1/2 Clinical Trial Application to FDA for Osteosarcoma Patients
[Asia Economy Reporter Minji Lee] Met팩토 announced on the 11th that it has submitted a Phase 1/2 clinical trial plan for single-agent Bactosertib therapy to the U.S. Food and Drug Administration (FDA) targeting adolescent and adult patients with recurrent refractory and progressive osteosarcoma.
Hot Picks Today
As Samsung Falters, Chinese DRAM Surges: CXMT Returns to Profit in Just One Year
- "Most Americans Didn't Want This"... Americans Lose 60 Trillion Won to Soaring Fuel Costs
- [Seoul, Now] Redevelopment Speed Pledge No.1: Without On-Site Insight, It Becomes the First Failure
- Samsung Union Member Sparks Controversy With Telegram Post: "Let's Push KOSPI Down to 5,000"
- "Why Make Things Like This?" Foreign Media Highlights Bizarre Phenomenon Spreading in Korea
The company stated, "We plan to evaluate the safety, tolerability, pharmacokinetics, and anticancer efficacy of single-agent Bactosertib therapy, and based on interim analysis results, we will assess safety and efficacy in a larger patient population."
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
